PneumRx, Inc. Raises $33 Million in Capital

Funds will be Used to Support European Sales of the PneumRx RePneu Lung Volume Reduction Coil (LVRC) System and to Conduct a Pivotal Clinical Trial to Support a PMA Application

MOUNTAIN VIEW, California, January 4, 2011 - PneumRx, Inc. (www.pneumrx.com), a medical device company
dedicated to bringing innovation and improvements to the treatment of lung
disease, today announced that it has raised $33 million in working capital
commitments. The oversubscribed round was led by Forbion Capital Partners and
co-led by Endeavour Vision, both leading venture capital firms from Europe,
and also included a prominent strategic corporate partner. The syndicate was
joined by existing investors Adams Street Partners, Telegraph Hill Partners,
Alta Partners, and Spray Venture Partners, among others. Silicon Valley Bank
and Leader Ventures also contributed to the capital raise in PneumRx.

PneumRx recently established a subsidiary in Germany, PneumRx GmbH, and
has begun selling its innovative RePneu Lung Volume Reduction Coil (LVRC)
System in Europe. It plans to use the funds to expand European
commercialization and to conduct an FDA-approved pivotal clinical trial to
support a PMA application. PneumRx expects to begin its pivotal clinical
trial in early 2011 and intends to submit its pivotal trial results to
support a PMA application to be able to sell the RePneu LVRC System in the
United States.

The RePneu LVRC System is a minimally invasive device intended to improve
lung function in emphysema patients by bronchoscopically implanting Nitinol
coils into the lungs to compress damaged tissue (lung volume reduction) and
restore elastic recoil to the lung. This treatment offers a minimally
invasive alternative to lung volume reduction surgery, and works
independently of collateral ventilation. More than 1500 LVR Coils have been
implanted to date in over 170 procedures. The LVRC System is CE Marked and is
currently available in select markets in Europe, with plans for broader
expansion.

"We are thrilled to have completed our Series C round and are pleased to
add a top-tier med-tech corporate partner in this later financing round. We
believe that this partnership will be extremely beneficial as PneumRx
prepares for its future pivotal trial, commercialization and reimbursement
efforts in the US. We also appreciate the addition of two prominent European
venture firms to our board. We look forward to working more closely with
Forbion and Endeavour Vision as we expand our commercial efforts in Europe,"
said Erin McGurk, Founder, President and CEO of PneumRx, Inc. "2010 was an
exciting year for PneumRx, receiving our CE Mark and achieving our first
European sales and we look forward to expanding into the US in 2011, with our
plans for our pivotal clinical trial. We are pleased to be able to bring our
RePneu Lung Volume Reduction Coil treatment to a greater number of emphysema
patients suffering from this debilitating disease."

Martien van Osch, Managing Partner at Forbion Capital Partners said,
"PneumRx brings an effective therapy for a large group of emphysema patients.
For most of these patients there are, to date, no good treatment
alternatives. Over 1500 coils have been implanted to date and the safety and
efficacy profile is very exciting. We are proud to lead this current
financing round and to help the company establish a presence and commercial
infrastructure in Europe."

Daniel Bertholet, Investment Director at Endeavour Vision, commented,
"Having reviewed all the companies in this sector, I am convinced that
PneumRx has developed the most promising Lung Volume Reduction device to
treat emphysema patients and is likely to become the preferred clinical
option in a few years. We are delighted to join the company in order to
support both the European market launch and the pivotal clinical study."

Martien van Osch and Daniel Bertholet will both join the Board of
Directors.

About PneumRx, Inc.

PneumRx, Inc. is a rapidly growing medical device company focused on the
development and commercialization of innovative products to treat emphysema
using minimally-invasive techniques. It is a privately held company located
in Mountain View, California. For more information, please visit
www.pneumrx.com.

About Forbion Capital Partners

Forbion Capital Partners is a dedicated Life Sciences venture capital
firm with offices in Naarden, The Netherlands, and Munich, Germany. For more
information, please visit www.forbion.com.

About Endeavour Vision

Endeavour Vision, located in Geneva, Switzerland, is a venture capital
investment firm which globally invests in both the Life Sciences and
Information/Communication Technology sectors. For more information, please
visit www.endeavourvision.com.

Erin McGurk, +1-650-625-8910, ext. 110, erin at pneumrx.com